Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue

Published:2007-07 Issue:1 Volume:51 Page:54-62
ISSN:0309-0167
Container-title:Histopathology
language:en
Short-container-title:Histopathology

Author:

Lindemann K,Resau J,Nährig J,Kort E,Leeser B,Annecke K,Welk A,Schäfer J,Vande Woude G F,Lengyel E,Harbeck N

Publisher

Wiley

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2559.2007.02732.x/fullpdf

Reference44 articles.

1. The receptor encoded by the human C-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors

2. Met, metastasis, motility and more

3. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells.

4. The met Proto-Oncogene Receptor and Lumen Formation

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk;Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies;2023

2. Expression of mesenchymal–epithelial transition factor in estrogen receptor-negative breast carcinoma;Journal of The Arab Society for Medical Research;2022-01

3. The FAM3C locus that encodes interleukin-like EMT inducer (ILEI) is frequently co-amplified in MET-amplified cancers and contributes to invasiveness;Journal of Experimental & Clinical Cancer Research;2021-02-17

4. HER2 Signaling in Breast Cancer;Advances in Experimental Medicine and Biology;2021

5. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer;Cancer Research and Treatment;2020-07-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3